Three points of attack in fight against restenosis

&

The 3 main processes involved in restenosis are currently being addressed by pharmaceutical research. New GPIIb/IIIa receptor antagonists look set to provide serious competition to conventional antiplatelet agents, such as aspirin and ticlopidine, in the prevention of thrombus formation. Agents that directly target neointimal proliferation, and even vascular remodelling, are also at various stages of development. A discussion of these approaches took place at the 44th Annual Scientific Sessions of the American College of Cardiology [ New Orleans, US; March 1995 ].